1. Stomach cancer: symptoms, life expectancy, how to treat stomach cancer
Stomach cancer, or gastric cancer, is a malignant tumor that affects the stomach cells. In nine out of ten cases, gastric cancers are adenocarcinomas, meaning that they develop in the inner (mucus) layer of the stomach.
more details...
2. FDA Approves Genentech’s Tecentriq in Combination With Avastin and Chemotherapy for the Initial Treatment of People With a Specific Type of Metastatic Lung Cancer.
announced that the U.S. Food and Drug Administration (FDA) approved Tecentriq® (atezolizumab), in combination with Avastin® (bevacizumab), paclitaxel and carboplatin (chemotherapy), for the initial (first-line) treatment of people with metastatic non-squamous non-small cell lung cancer
more details...
3. Drug Approvals for the 2 Most Common Types of Cancer in the Last 2 Years
According to the American Cancer Society, almost 601,000 people in the U.S. died of cancer in 2017. The two most common types of cancer are lung cancer and breast cancer, followed by colorectal cancer, prostate cancer and stomach cancer.
more details...
4. Lilly's CYRAMZA® (ramucirumab) Receives FDA Approval as First-Line Treatment for Metastatic EGFR-Mutated Non-Small Cell Lung Cancer
CYRAMZA, in combination with erlotinib, now approved for the treatment of people with untreated metastatic non-small cell lung cancer (NSCLC) with certain activating EGFR mutations, based on the positive global Phase 3 RELAY study.
more details...
5. New Target to Attack in Stomach Cancer
Patients with untreated advanced gastric or gastroesophageal junction (GEJ) cancer lived longer without disease progression with the addition of a fibroblast growth factor receptor (FGFR) inhibitor to chemotherapy, a randomized trial showed.
more details...
6. BMS aims for US approval of Opdivo combo in stomach cancer
The US Food and Drug Administration (FDA) has accepted a priority review for Bristol Myers Squibb’s (BMS) Opdivo (nivolumab) plus chemotherapy combination in stomach cancer.
more details...
7. FDA permits marketing of new endoscopic device for treating gastrointestinal bleeding
Today, the U.S. Food and Drug Administration permitted marketing of Hemospray, a new device used to help control certain types of bleeding in the gastrointestinal (GI) tract.
more details...